Source comparison
Dosing Structure for Post-Surgical vs Conservative ACL Recovery
Post-surgical ACL reconstruction (using autograft or allograft tissue) creates an acute inflammatory response that peaks 48–72 hours after the procedure. BPC-157 shows the strongest preclinical evidence when administered during this early inflammatory window,
This comparison does not assign a generated winner or score.
- Post-surgical ACL reconstruction (using autograft or allograft tissue) creates an acute inflammatory response that peaks 48–72 hours after the procedure. BPC-157 shows the strongest preclinical evidence when administered during this early inflammatory window, before granulation tissue forms. Standard research dosing ranges from 200–500 mcg daily via subcutaneous injection, either systemically or peri-injury (localized near the surgical site). The peri-injury approach. Injecting within 2–3 cm of the graft site. Increases local tissue concentrations but requires sterile technique and anatomical precision.
- TB-500 enters the protocol during the proliferative phase, typically starting 5–7 days post-surgery once the acute inflammatory cascade has resolved. Research dosing ranges from 2–5 mg administered twice weekly, reflecting TB-500's longer half-life compared to BPC-157. The dosing frequency difference matters: BPC-157's effects on VEGFR2 are dose-dependent and time-limited, requiring daily administration to maintain receptor upregulation. TB-500's effects on actin dynamics persist longer, allowing less frequent dosing while maintaining cell migration benefits.
- For conservative (non-surgical) ACL recovery. Typically reserved for partial tears or low-demand patients. The timeline compresses. Without surgical debridement, the inflammatory phase extends 7–10 days, and fibroblast infiltration begins earlier. Conservative protocols often use BPC-157 starting immediately post-injury for 10–14 days, then transition to TB-500 for weeks 2–6. The challenge: without surgical stabilization, mechanical loading during the remodeling phase can disrupt collagen alignment regardless of peptide support.